Jump to main content
eTG Complete
Index
Search
Home
Antibiotic
Pneumonia
Ventilator-associated pneumonia
VAP in patients at increased risk of infection with Pseudomonas aeruginosa
Antibiotic
Bartonella infections
Osteomyelitis
Septic arthritis of a native joint
Bone and joint infections other than osteomyelitis and native joint septic arthritis
Sepsis or septic shock associated with a bone or joint source
Directed therapy for native bone or joint infection
Brucellosis
Infective endocarditis
Cardiovascular system infections other than endocarditis
Central nervous system infections
Coronavirus disease 2019 (COVID-19)
Cryptococcosis
Cytomegalovirus (CMV) infection
Infectious diarrhoea
Ear, nose and throat infections
Eye infections
Febrile neutropenia
Genital and sexually transmissible infections
Human immunodeficiency virus
Intra-abdominal infections
Leptospirosis
Lyme disease
Mediastinitis
Melioidosis
Mpox (monkeypox)
Nocardiosis
Nontuberculous mycobacterial infections
Oesophageal infections
Parasitic infections
Perinatal infections
Prevention of infection
Q fever
Pneumonia
Finding the right pneumonia topic in these guidelines
Community-acquired pneumonia (CAP) in adults
Community-acquired pneumonia (CAP) in children 2 months or older
Community-acquired pneumonia (CAP) in term neonates and children younger than 2 months
Community-acquired pneumonia (CAP) in residents of an aged-care facility
Hospital-acquired pneumonia
Ventilator-associated pneumonia
What is VAP?
Aetiology of VAP
Diagnosis of VAP
Microbiological investigations for VAP
Approach to managing VAP
VAP in patients at low risk of infection with Pseudomonas aeruginosa
VAP in patients at increased risk of infection with Pseudomonas aeruginosa
Empirical therapy for VAP in patients at increased risk of infection with Pseudomonas aeruginosa
Additional therapy for VAP in patients at increased risk of infection with Pseudomonas aeruginosa
Review of patients with VAP
De-escalation of therapy and intravenous to oral switch for VAP
Duration of therapy for VAP
Follow-up for patients with VAP
Approach to managing patients with VAP who are not improving
Role of biomarkers for management of VAP
Prevention of VAP
References
Aspiration pneumonia
Directed therapy for pneumonia
Respiratory tract infections other than pneumonia
Acute rheumatic fever
Rickettsial infections
Salivary gland infections
Sepsis and septic shock: Identification and initial management
Sepsis and septic shock: Empirical regimens
Directed therapy for bloodstream infections, including sepsis and septic shock
Skin and soft tissue infections
Traumatic wound infections
Urinary tract infections in adults
Urinary tract infections in children
Identifying resistant pathogens or Candida species
Principles of obtaining blood for culture
Principles of antimicrobial use
Antimicrobial stewardship (AMS)
Practical information on using antimicrobial drugs
Aminoglycoside use
Vancomycin use in adults
Vancomycin use in young infants and children
Monitoring antimicrobial blood concentrations
Ambulatory antimicrobial therapy
Antimicrobial hypersensitivity
Kidney impairment and antimicrobial dosing
Contact details for health departments and public health units
Amikacin initial dose calculator
Gentamicin initial dose calculator
Tobramycin initial dose calculator
VAP in patients at increased risk of infection with Pseudomonas aeruginosa
Empirical therapy for VAP in patients at increased risk of infection with Pseudomonas aeruginosa
Additional therapy for VAP in patients at increased risk of infection with Pseudomonas aeruginosa
